Beta Bionics, Inc.

Beta Bionics designs and commercializes automated insulin delivery systems for people with insulin-requiring diabetes. The company's primary product is the iLet Bionic Pancreas, an insulin delivery device approved for type 1 diabetes in adults and children six years and older. The device automates insulin dosing to reduce the burden of manual management. The company is also developing the Patch Pump, a tubeless insulin pump designed to adhere directly to skin, and the Bihormonal iLet, which combines automated delivery of both insulin and glucagon to more closely mimic pancreatic function.

Beta Bionics has established partnerships to expand its product pipeline and capabilities. The company holds a collaboration agreement with Xeris Pharmaceuticals to develop a pump-compatible glucagon formulation, and has a development and commercialization agreement with Abbott Diabetes Care to create an automated insulin delivery system. These partnerships reflect the company's strategy to integrate multiple hormone delivery mechanisms and leverage established distribution channels.

The company operates with approximately 420 full-time employees and is headquartered in Irvine, California. Beta Bionics was incorporated in Delaware in 2015 and trades on the Nasdaq exchange. The company is in the commercial stage, having brought its primary iLet product to market while continuing to advance its pipeline of next-generation delivery systems.